Immune Thrombocytopenia clinical trials at UCSF
1 research study open to eligible people
Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children
open to eligible people ages 1-18
This is an investigator initiated, multicenter, open label, randomized phase 3 study for subjects with newly diagnosed ITP from ages 1 to less than 18 years old.
San Francisco, California and other locations